This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Circulation, Volume 150, Issue Suppl_1 , Page A4144084-A4144084, November 12, 2024. Despite being a hearttransplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations.
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:In hearttransplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after hearttransplantation is associated with long-term adverse outcomes is unknown.
Pictured Left to Right: Members and students of the McGill Gene Editing Laboratory at The Texas Heart Institute in Houston, Texas: Fansen Meng, PhD, Xiao Li, PhD, James Martin, MD, PhD, Rich Li, PhD (back), Maggie Lim (undergraduate student at Rice University front), Yuka Morikawa, PhD, Ann Bromley.
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 452-461, October 1, 2023. Background:Many cardiovascular disorders propel the development of advanced heartfailure that necessitates cardiac transplantation.
Dilation: The chambers of the heart expand, making the walls thinner. Both forms of enlargement may compromise the heart’s ability to pump blood efficiently, leading to further complications like heartfailure. What Causes an Enlarged Heart? Here are some of the most common causes: 1.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Clinical evaluation of central venous pressure is difficult, depends on experience, and is often inaccurate in patients with chronic advanced heartfailure. 0.84]) and confirmed in the validation cohort (receiver operating characteristic, 0.82 [95% CI, 0.73–0.92]).
Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Hearttransplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5
.: 882 Dates Distributed: March 1, 2021 to present Date Initiated by Firm: March 13, 2024 Device Use The HeartMate 3 Left Ventricular Assist System (LVAS) is used to help the heart pump blood when it is not able to do so effectively on its own. The device is used both inside and outside of the hospital.
Circulation: HeartFailure, Ahead of Print. Centers performing at least 1 hearttransplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state. Since mammals cannot regenerate cardiac muscle cells on their own, hearttransplants are currently the only clinically viable option for patients suffering (or likely to suffer) heartfailure.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:In 2018, an algorithm-based allocation system for hearttransplantation (HT) was implemented in France.
.: 13,883 Date Initiated by Firm: February 19, 2024 Device Use The HeartMate II and HeartMate 3 Left Ventricular Assist Systems (LVAS) are used to help the heart pump blood when it's not able to do so effectively on its own. Both devices work by taking over the pumping function of the left ventricle, the main pumping chamber of the heart.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heartfailure with reduced ejection fraction, and it is associated with poor prognosis.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in hearttransplantation.
Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with hearttransplant who had EMB were compared to those without hearttransplant who did not have EMB p=0.001.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among hearttransplantation (HT) recipients. Elevated dd-cfDNA was defined as 0.12%.RESULTS:Two 0.71%];P=0.38).
Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Hearttransplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.
Circulation, Ahead of Print. BACKGROUND:Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). The Impella CP is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation. It is able to deliver 3.5L/min
J Electrocardiol, 42 (2009), pp. e5 Article Download PDF Google Scholar 3 RNW Hauer, MGPJ Cox, JA Groeneweg Impact of new electrocardiographic criteria in arrhythmogenic cardiomyopathy Front Physiol, 3 (2012), p.
Circulation: HeartFailure, Ahead of Print. Background:Black hearttransplant patients are at higher risk of acute rejection (AR) and death than White patients. In a multivariable model, Black patient race (hazard ratio, 2.61 [95% CI, 1.35–5.04];P=0.004) 5.04];P=0.004) and %dd-cfDNA (hazard ratio, 1.15 [95% CI, 1.03–1.28];P=0.010)
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 421-430, October 1, 2023. Background:Variants in theDMDgene, that encodes the cytoskeletal protein, dystrophin, cause a severe form of dilated cardiomyopathy (DCM) associated with high rates of heartfailure, hearttransplantation, and ventricular arrhythmias.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content